Leqvio FDA Approval
Despite the availability of lipid-lowering therapy, significant
unmet need remains in ASCVD
Clinical unmet need
80% of statin-treated ASCVD patients currently not at LDL-C goal¹
Non-clinical unmet need
A1 Adherence
Real-world challenges to
adherence compromise
outcomes²
A2 Access
A3 Affordability
Considerable access hurdles
for current treatments
Patient out-of-pocket costs
can be a barrier to access
ASCVD Atherosclerotic Cardiovascular Disease LDL-C - Low Density Lipoprotein Choletsterol 1. Wong ND. Journal of Clinical Lipidology. 2016;10(5):1109-1118 2. The effect of LeqvioⓇ on cardiovascular morbidity and mortality is
currently being studied in the ongoing Phase III ORION-4 and VICTORION-2P trials.
17 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation
V NOVARTIS | Reimagining MedicineView entire presentation